Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Long Wait Isn't Over for Immunomedics

More than three years after filing its PLA for ImmuRAID-CEA for colorectal cancer imaging, Immunomedics Inc. (IMMU) received a not approvable letter from the

Read the full 240 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE